治疗相关慢性粒单核细胞白血病不具有治疗相关肿瘤的高危特征
该研究比较了71例治疗相关慢性粒单核细胞白血病(tCMML)与461例原发CMML(dnCMML)的特征。tCMML中染色体7异常和TP53突变频率更高,但复杂核型无差异,且NRAS和CBL突变频率更低。tCMML与原发CMML的中位总生存无显著差异,但既往化疗与死亡风险增加相关。
要点
- tCMML中染色体7异常频率为4%,原发CMML为13%(P = .005)。
- tCMML中TP53突变频率为4%,原发CMML为12%(P = .04)。
- tCMML与原发CMML中位总生存无显著差异(34.7个月 vs 35.9个月,P = .26)。
核心结论
- tCMML不具有治疗相关肿瘤的高危特征和不良结局。
研究设计与样本
- 分析71例治疗相关慢性粒单核细胞白血病(tCMML)患者,并与461例原发CMML(dnCMML)患者进行比较。
主要发现
- 从细胞毒治疗到tCMML诊断的中位时间为6.5年。
- tCMML中染色体7异常频率为4%,原发CMML为13%(P = .005);复杂核型频率为3% vs 7%(P = .15)。
- tCMML中TP53突变频率为4%,原发CMML为12%(P = .04);NRAS突变频率为6% vs 22%(P = .007);CBL突变频率为4% vs 12%(P = .04)。
- 既往抗代谢药物治疗与NF1和SETBP1突变相关(OR,1.22;95% CI,1.05-1.42;P = .01);既往有丝分裂抑制剂治疗与NF1和SETBP1突变相关(OR,1.24;95% CI,1.06-1.44;P = .009),并与较低TET2突变频率相关(OR,0.71;95% CI,0.55-0.92;P = .01)。
- tCMML与原发CMML中位总生存无显著差异(34.7个月 vs 35.9个月,P = .26);多因素分析显示既往化疗与死亡风险增加相关(HR,1.76;95% CI,1.07-2.89;P = .026)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Therapy-related myeloid neoplasms (t-MNs) arise after exposure to cytotoxic therapies and are associated with high-risk genetic features and poor outcomes. We analyzed a cohort of patients with therapy-related chronic myelomonocytic leukemia (tCMML; n = 71) and compared its features to that of de novo CMML (dnCMML; n = 461). Median time from cytotoxic therapy to tCMML diagnosis was 6.5 years. Compared with dnCMML, chromosome-7 abnormalities (4% vs 13%; P = .005) but not complex karyotype (3% vs 7%; P = .15), were more frequent in tCMML. tCMML was characterized by higher TP53 mutation frequency (4% vs 12%; P = .04) and lower NRAS (6% vs 22%, P = .007) and CBL (4% vs 12%, P = .04) mutation frequency. Prior therapy with antimetabolites (odd ratio [OR], 1.22; 95% confidence interval [CI], 1.05-1.42; P = .01) and mitotic inhibitors (OR, 1.24; 95% CI, 1.06-1.44; P = .009) was associated with NF1 and SETBP1 mutations whereas prior mitotic inhibitor therapy was associated with lower TET2 mutation frequency (OR, 0.71; 95% CI, 0.55-0.92; P = .01). Although no differences in median overall survival (OS) were observed among tCMML and dnCMML (34.7 months vs 35.9 months, P = .26), multivariate analysis for OS revealed that prior chemotherapy was associated with increased risk of death (hazard ratio, 1.76; 95% CI, 1.07-2.89; P = .026). Compared with a cohort of therapy-related myelodysplastic syndrome, tCMML had lower TP53 mutation frequency (12% vs 44.4%, P < .001) and less unfavorable outcomes. In summary, tCMML does not exhibit the high-risk features and poor outcomes of t-MNs.
引用
- Bataller A, Gener-Ricos G, Almanza-Huante E, et al. Therapy-related chronic myelomonocytic leukemia does not have the high-risk features of a therapy-related neoplasm. Blood Adv. 2024. PMID: 38513082. doi:10.1182/bloodadvances.2024012565
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。